Physicians treating persons with diabetes should be aware of the new understandings of the causes and consequences of insulin resistance in young patients.

LEARNING OBJECTIVES

At the end of this activity, the participant should be able to:

1. Discuss the pathogenesis and potential adverse effects of nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH)

2. Explain aspects of the development of insulin resistance during childhood.

3. Properly interpret the implications of insulin resistance on clinical management of diabetic youth.

TARGET AUDIENCE:  Physicians treating persons with diabetes mellitus.

INSTRUCTIONS FOR COMPLETING THIS COURSE

After reading the article in the journal and reflecting on the information presented, participants may register to complete the exam and course evaluation online. 

There are 8 multiple choice questions presented in this course.  A minimum grade of 70% (6 correct answers) must be achieved in order to obtain CME credit.  

The course software does not permit you to page back from the exam questions.  You must be sure that you understand the material presented on before proceeding.  When you have submitted your exam, the Course Results page will display. This page will contain your final grade and allow you to immediately view/print your Certificate if you have achieved the minimum passing score. 

 If you wish to obtain more information regarding the features of this site, you may visit the Orientation page.  Click here to view Orientation.

Physicians are provided with two opportunities to complete the course presented here. 

ACCREDITATION STATEMENT

Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Mount Sinai School of Medicine designates each educational activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is the policy of Mount Sinai School of Medicine to ensure objectivity, balance, independence, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices.

Disclosure: Dr. Bloomgarden has disclosed that he is a member of the speakers’ bureau of Takeda, GlaxoSmithKline, Novartis, NovoNordisk, EliLilly, Amylin, and Merck. The editor has no relationships with pharmaceutical companies or manufacturers of products to disclose. This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of disease. Some uses of these agents have not been approved by the US Food and Drug Administration. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

CONTACT INFORMATION

Questions regarding course content may be directed to Dr. Zachary Bloomgarden at zbloomgard@aol.com.

If you require technical assistance with completing this course, please contact Continuing Education Online Customer Service at 888-345-6788 (toll free) or 718-648-8080 or send e-mail to CEO.support6@proceo.com.

PRIVACY POLICY

Your privacy and security are of great importance to our company.  Our detailed Privacy Policy is available for you to review at any time.  Click here to view our Privacy Policy.